Emerald Health Pharmaceuticals — Biomedical Watch V2

Traitements5programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

5

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
EHP-101 25 mg BIDThe purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with Relapsing Forms of Multiple Sclerosis (RMS).	SEP	Phase 2	À vérifier	United States, Australia	À vérifier
EHP-101 25 mg ODThe purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with Relapsing Forms of Multiple Sclerosis (RMS).	SEP	Phase 2	À vérifier	United States, Australia	À vérifier
EHP-101 50 mg BIDThe purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with Relapsing Forms of Multiple Sclerosis (RMS).	SEP	Phase 2	À vérifier	United States, Australia	À vérifier
EHP-101 50 mg ODThe purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with Relapsing Forms of Multiple Sclerosis (RMS).	SEP	Phase 2	À vérifier	United States, Australia	À vérifier
EHP-101 25 mg ODThe purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with Relapsing Forms of Multiple Sclerosis (RMS).	SEP	Phase 2	À vérifier	United States, Australia	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
EHP-101 25 mg OD	SEP	Phase 2	NCT04909502	Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis	SUSPENDED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.